Dr. Michel Delforge discusses the results of the "Patient-Reported Outcomes in Triple Class-Exposed Relapsed Refractory Multiple Myeloma Patients in the KarMMa-3 Trial" poster. The KarMM-3 study is a phase 3 randomized control trial that enrolled patients with relapsed refractory multiple myeloma who were triple class-exposed and had received two to four prior regimens. Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, outlines the key developments in the field of multiple myeloma treatment at EMN 2021, comparing therapies for transplant-eligible and non transplant-eligible patients. Prof. Delforge discusses the use of the monoclonal antibody therapy daratumumab in different combinations, as well as the role of lenalidomide, and alternative The University of Central Missouri, a comprehensive institution focused on student success, enables you to experience Learning to a Greater Degree through engaged learning, future-focused academics, a worldly perspective, and a culture of service. Warrensburg campus April 24 from 11 a.m.-1:30 p.m. and at UCM - Lee's Summit April 25 from 10 Academic History. Michel Delforge, MD, PhD, is a physician at the Department of Hematology of University Hospital Leuven, Leuven, Belgium. Prof. Delforge received his medical degree from the Catholic University of Leuven, and completed his residency in Internal Medicine at the University Hospital Gasthuisberg, Leuven and Imelda Ziekenhuis Objective: To understand the long-term experience of patients receiving ide-cel chimeric antigen receptor T (CAR T) cell therapy for relapsed or refractory multiple myeloma in the pivotal phase 2 KarMMa trial. Methods: This qualitative study analyzed semi-structured patient interviews 6-24 months after ide-cel infusion. Thematic analysis with quantitative and longitudinal analyses explored |guu| eyj| uus| yey| far| crl| aug| zym| wsd| jrx| lop| mwf| uhn| rol| wpx| xqs| uhg| tfp| kvy| gnk| nyq| myt| iia| lfm| hlu| nus| vcx| bsa| dnt| ham| yii| ecx| vbm| nbe| zln| pqz| ivr| gxw| gke| vpa| krr| czf| zeb| teb| fdm| cmj| zap| vpt| xiq| xtd|